STK11 and non-small cell lung carcinoma: Similar observations have been made with adagrasib, with confirmed ORRs of 40.5%, 28.6%, and 51.4% in patients with STK11, KEAP1, and TP53 mutations, respectively, and higher response rates in those with STK11-mutant/KEAP1-wild-type tumors (44.0%) than in those with STK11-wild-type/KEAP1-mutant tumors (14.3%).200 Similarly, STK11, KEAP1, and TP53 resulted in a lower response (compared with wild type) in patients with NSCLC treated with divarasib and IBI351.201,202